Feasibility of Using Molecular Docking-Based Virtual Screening for Searching Dual Target Kinase Inhibitors
暂无分享,去创建一个
[1] Richard M. Jackson,et al. Binding Site Similarity Analysis for the Functional Classification of the Protein Kinase Family , 2009, J. Chem. Inf. Model..
[2] Péter Csermely,et al. The efficiency of multi-target drugs: the network approach might help drug design. , 2004, Trends in pharmacological sciences.
[3] B. Stockwell,et al. Multicomponent therapeutics for networked systems , 2005, Nature Reviews Drug Discovery.
[4] R. Atkins,et al. Urine macrophage migration inhibitory factor reflects the severity of renal injury in human glomerulonephritis. , 2002, Journal of the American Society of Nephrology : JASN.
[5] Eric J. Martin,et al. Profile-QSAR: A Novel meta-QSAR Method that Combines Activities across the Kinase Family To Accurately Predict Affinity, Selectivity, and Cellular Activity , 2011, J. Chem. Inf. Model..
[6] R. Abagyan,et al. Flexible ligand docking to multiple receptor conformations: a practical alternative. , 2008, Current opinion in structural biology.
[7] S. Wilhelm,et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer , 2007, Nature Reviews Drug Discovery.
[8] P. Cozzini. Target Flexibility: An Emerging Consideration in Drug Discovery and Design , 2009 .
[9] G. Barton,et al. Multiple protein sequence alignment from tertiary structure comparison: Assignment of global and residue confidence levels , 1992, Proteins.
[10] Boon Chuan Low,et al. In-Silico Approaches to Multi-target Drug Discovery , 2010, Pharmaceutical Research.
[11] Richard Morphy,et al. From magic bullets to designed multiple ligands. , 2004, Drug discovery today.
[12] Simone Sciabola,et al. Predicting Kinase Selectivity Profiles Using Free‐Wilson QSAR Analysis. , 2008 .
[13] Huijong Han,et al. Discovery of a potential allosteric ligand binding site in CDK2. , 2011, ACS chemical biology.
[14] J. Lehár,et al. Multi-target therapeutics: when the whole is greater than the sum of the parts. , 2007, Drug discovery today.
[15] T. N. Bhat,et al. The Protein Data Bank , 2000, Nucleic Acids Res..
[16] L. Wodicka,et al. A small molecule–kinase interaction map for clinical kinase inhibitors , 2005, Nature Biotechnology.
[17] Robert P. Sheridan,et al. Multiple protein structures and multiple ligands: effects on the apparent goodness of virtual screening results , 2008, J. Comput. Aided Mol. Des..
[18] R. Morphy. Selectively nonselective kinase inhibition: striking the right balance. , 2010, Journal of medicinal chemistry.
[19] G. Scapin. Structural biology in drug design: selective protein kinase inhibitors. , 2002, Drug discovery today.
[20] Satoshi Niijima,et al. Dissecting Kinase Profiling Data to Predict Activity and Understand Cross-Reactivity of Kinase Inhibitors , 2012, J. Chem. Inf. Model..
[21] Stephen R. Johnson,et al. Trends in kinase selectivity: insights for target class-focused library screening. , 2011, Journal of medicinal chemistry.
[22] Matthew P. Repasky,et al. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. , 2004, Journal of medicinal chemistry.
[23] J. Drews. Drug discovery: a historical perspective. , 2000, Science.
[24] Yuri Pevzner,et al. Virtual Target Screening: Validation Using Kinase Inhibitors , 2012, J. Chem. Inf. Model..
[25] Susan O'Brien,et al. Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure. , 2007, Blood.
[26] Somesh D. Sharma,et al. Managing protein flexibility in docking and its applications. , 2009, Drug discovery today.
[27] Keun Woo Lee,et al. Molecular Docking and Pharmacophore Filtering in the Discovery of Dual-Inhibitors for Human Leukotriene A4 Hydrolase and Leukotriene C4 Synthase , 2011, J. Chem. Inf. Model..
[28] Mindy I. Davis,et al. A quantitative analysis of kinase inhibitor selectivity , 2008, Nature Biotechnology.
[29] K Schulten,et al. VMD: visual molecular dynamics. , 1996, Journal of molecular graphics.
[30] Eric J. Martin,et al. Kinase-Kernel Models: Accurate In silico Screening of 4 Million Compounds Across the Entire Human Kinome , 2012, J. Chem. Inf. Model..
[31] Jiri Gut,et al. Identification of novel parasitic cysteine protease inhibitors using virtual screening. 1. The ChemBridge database. , 2004, Journal of medicinal chemistry.
[32] Zhinan Yin,et al. A Small-Molecule Macrophage Migration Inhibitory Factor Antagonist Protects against Glomerulonephritis in Lupus-Prone NZB/NZW F1 and MRL/lpr Mice , 2011, The Journal of Immunology.
[33] Y Z Chen,et al. Virtual screening of selective multitarget kinase inhibitors by combinatorial support vector machines. , 2010, Molecular pharmaceutics.
[34] Alex Matter,et al. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug , 2002, Nature Reviews Drug Discovery.
[35] Xin Wen,et al. BindingDB: a web-accessible database of experimentally determined protein–ligand binding affinities , 2006, Nucleic Acids Res..
[36] Ian Collins,et al. Measuring and interpreting the selectivity of protein kinase inhibitors , 2009, Journal of chemical biology.
[37] P. Zarrinkar,et al. High-throughput kinase profiling as a platform for drug discovery , 2008, Nature Reviews Drug Discovery.
[38] R. Gozalbes,et al. Development and experimental validation of a docking strategy for the generation of kinase-targeted libraries. , 2008, Journal of medicinal chemistry.
[39] Jarl E. S. Wikberg,et al. Kinome-wide interaction modelling using alignment-based and alignment-independent approaches for kinase description and linear and non-linear data analysis techniques , 2010, BMC Bioinformatics.
[40] Robert P. Sheridan,et al. QSAR Models for Predicting the Similarity in Binding Profiles for Pairs of Protein Kinases and the Variation of Models between Experimental Data Sets , 2009, J. Chem. Inf. Model..
[41] Ariel Fernández,et al. In silico drug profiling of the human kinome based on a molecular marker for cross reactivity. , 2008, Molecular pharmaceutics.
[42] Krystal J Alligood,et al. A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib) , 2004, Cancer Research.
[43] R. Friesner,et al. Evaluation and Reparametrization of the OPLS-AA Force Field for Proteins via Comparison with Accurate Quantum Chemical Calculations on Peptides† , 2001 .
[44] R. Figlin,et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[45] R. Abagyan,et al. Systematic Exploitation of Multiple Receptor Conformations for Virtual Ligand Screening , 2011, PloS one.
[46] 宁北芳,et al. 疟原虫var基因转换速率变化导致抗原变异[英]/Paul H, Robert P, Christodoulou Z, et al//Proc Natl Acad Sci U S A , 2005 .
[47] William L. Jorgensen,et al. Journal of Chemical Information and Modeling , 2005, J. Chem. Inf. Model..
[48] S. Knapp,et al. A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases , 2007, Proceedings of the National Academy of Sciences.
[49] Yan Xu,et al. [Multi-target therapeutics and new drug discovery]. , 2009, Yao xue xue bao = Acta pharmaceutica Sinica.